Leerink analyst Jonathan Chang raised the firm’s price target on Nanobiotix (NBTX) to $37 from $26 and keeps an Outperform rating on the shares after the company reported Q4 results and provided a pipeline update that the firm says was in line with expectations. The firm’s raised target reflects the results and its updated estimates, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix Extends Cash Runway to 2028 as JNJ-1900 Oncology Program Advances and 2025 Results Filed
- Robust Phase 2 CONVERGE Data for JNJ-1900 Underpin Buy Rating and €32 Price Target on Nanobiotix
- Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright
- Nanobiotix presents first data from CONVERGE study
- Nanobiotix Reports First Positive Phase 2 Data for NBTXR3 in Inoperable Stage 3 Lung Cancer